2020
October
AACR Tumor Immunology and Immunotherapy 2020
October 28, 2020
Last week, the ACIR team attended the AACR Tumor Immunology and Immunotherapy conference that virtually took place in Boston, MA. This week’s extensive special feature covers select sessions from the conference. We have organized the content by topics below. Approaches to T cell priming and vaccines Regulators of tumor immunityMyeloid Compartment in the TMECAR...
Intracellular PD-L1 signaling guides the DC home
October 21, 2020
While the effect of PD-1 signaling in T cells in response to binding with PD-L1 has been reasonably well established, PD-L1 signaling via its cytoplasmic domain, so-called PD-L1 reverse signaling, has not been broadly studied. In tumor cells, PD-L1 reverse signaling protects the cells from IFN-induced cell death, but its effects on antigen-presenting...
A new internal T cell checkpoint: CISH
October 14, 2020
PD-1 and other known markers of activation and exhaustion have helped researchers to understand T cell biology and develop numerous immunotherapies. While many of these markers are well known and well studied, there are likely more that have yet to be investigated. Looking into the relationship between PD-1 and other markers of activation...
PD-L1 and PD-1 mediate T cell suppression, but not where you think
October 7, 2020
Targeting the PD-1/PD-L1 axis is a common immunotherapeutic strategy that works well in some, but not all patients with cancer. Typically, researchers have looked at interactions between PD-1 and PD-L1 within tumors to explain the mechanism behind this treatment; however, this has never fully explained the efficacy, or lack thereof, of PD-1/PD-L1 blockade...
